Overall rank by patents
#39,212
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Bioresponse, L.l.c.
USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, active 2016–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: Y02A (TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE).
6
Total patents granted
4
CPC technology areas
24.3
Avg claims per patent
-50%
5-year filing velocity
The verdict
Bioresponse holds 6 US patents across 4 technology areas, rank #39,212 of 50,000 tracked assignees.
- #39,212
- of 50,000 US assignees by volume
- Top 61%
- by Innovation Score (31.7/100)
- 24.3
- avg claims per patent
- -50%
- filing velocity, last 5 yrs
Portfolio overview
Bioresponse, L.l.c. has been granted 6 US utility patents between 2016 and 2022, placing Bioresponse, L.l.c. at rank #39,212 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.3 claims per patent with primary concentration in Y02A (TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE). As a US Corporation, Bioresponse, L.l.c. is one of the more focused assignees in the PatentsView dataset. By volume, Bioresponse sits between Biomineral Systems Llc (6 patents, rank #39,208) and Black Bart, Inc. (6 patents, rank #39,216) - the closest US assignees by grant volume. The composite Innovation Score of 31.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 4 in the 2015–2019 window, a -50% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Bioresponse, L.l.c.'s 24.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Bioresponse, L.l.c. against peers pursuing similar technology classes.
Who files at Bioresponse's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Biomineral Systems
Biomineral Systems LLC
6 patents
- Bionic Stork
Bionic Stork Ltd.
6 patents
- Bioniko Consulting
Bioniko Consulting LLC
6 patents
- Biopharm Gesellsc…
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung von Pharmaka MBH
6 patents
- Biota Technology
Biota Technology, Inc.
6 patents
- Biscotti
Biscotti Inc.
6 patents
- Bizzybee
Bizzybee LLC
6 patents
- Black Bart
Black Bart, Inc.
6 patents
- Bioresponse L L C ◀
Bioresponse, L.L.C.
6 patents
What this shows Bioresponse holds 6 patents at rank #39,212, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Bioresponse
By rank, the assignees closest to #39,212 in granted patent volume.
- Biomineral Systems Llc #39,208 · 6 patents
- Bionic Stork Ltd. #39,209 · 6 patents
- Bioniko Consulting Llc #39,210 · 6 patents
- Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka MBH #39,211 · 6 patents
- Biota Technology, Inc. #39,213 · 6 patents
- Biscotti Inc. #39,214 · 6 patents
- Bizzybee Llc #39,215 · 6 patents
- Black Bart, Inc. #39,216 · 6 patents
Leaders in Y02A (Technologies FOR Adaptation TO Climate Change)
Other assignees with the most granted patents in Bioresponse's primary technology class.
- Monsanto Technology Llc 369 in class
- The Regents Of The University Of California 309 in class
- Dexcom, Inc. 263 in class
- Pioneer Hi-bred International, Inc. 186 in class
- Glaxosmithkline Biologicals Sa 180 in class
- Massachusetts Institute Of Technology 163 in class
- DOW Agrosciences Llc 156 in class
- The Board Of Regents Of The University Of Texas System 133 in class
Bioresponse's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 61% higher than 39% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 16.7% |
| 2017 | 1 | 16.7% |
| 2018 | 1 | 16.7% |
| 2019 | 1 | 16.7% |
| 2020 | 1 | 16.7% |
| 2022 | 1 | 16.7% |
Which technologies does Bioresponse, L.l.c. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Bioresponse, L.l.c. hold?
Bioresponse, L.l.c. holds 6 US granted patents filed between 2016 and 2022, spanning 4 technology areas.
What is Bioresponse, L.l.c.'s Innovation Score?
Bioresponse, L.l.c. has an Innovation Score of 31.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Bioresponse, L.l.c. focus on?
Bioresponse, L.l.c.'s top technology area is Y02A (TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE) with 6 patents. The company has filed patents in 4 CPC subclasses total.
Is Bioresponse, L.l.c.'s patent filing rate increasing or decreasing?
Bioresponse, L.l.c.'s recent filing velocity is -50% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Bioresponse, L.l.c.'s patents?
Bioresponse, L.l.c.'s patents average 24.3 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Bioresponse, L.l.c. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Bioresponse's 6 grants land it in the top 61% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Bioresponse ranks #39,212 of 50,000. Top 50 holders
- Most of this portfolio concentrates in Y02A - see who else leads that technology area. Y02A leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.